ABSTRACT
The TRIO gene encodes a rho guanine exchange factor, the function of which is to exchange GDP to GTP, and hence to activate Rho GTPases, and has been described to impact neurodevelopment. Specific genotype-to-phenotype correlations have been established previously describing striking differentiating features seen in variants located in specific domains of the TRIO gene that are associated with opposite effects on RAC1 activity. Currently, 32 cases with a TRIO gene alteration have been published in the medical literature. Here, we report an additional 25, previously unreported individuals who possess heterozygous TRIO variants and we review the literature. In addition, functional studies were performed on the c.4394A > G (N1465S) and c.6244-2A > G TRIO variants to provide evidence for their pathogenicity. Variants reported by the current study include missense variants, truncating nonsense variants, and an intragenic deletion. Clinical features were previously described and included developmental delay, learning difficulties, microcephaly, macrocephaly, seizures, behavioral issues (aggression, stereotypies), skeletal problems including short, tapering fingers and scoliosis, dental problems (overcrowding/delayed eruption), and variable facial features. Here, we report clinical features that have not been described previously, including specific structural brain malformations such as abnormalities of the corpus callosum and ventriculomegaly, additional psychological and dental issues along with a more recognizable facial gestalt linked to the specific domains of the TRIO gene and the effect of the variant upon the function of the encoded protein. This current study further strengthens the genotype-to-phenotype correlation that was previously established and extends the range of phenotypes to include structural brain abnormalities, additional skeletal, dental, and psychiatric issues.
Subject(s)
Microcephaly , Nervous System Malformations , Humans , Phenotype , Mutation , Mutation, Missense , Microcephaly/geneticsABSTRACT
Mohr-Tranebjærg syndrome is an X-linked syndrome characterized by sensorineural hearing impairment in childhood, followed by progressive neurodegeneration leading to a broad phenotypic spectrum. Genetically MTS is caused by pathogenic variants in the TIMM8A gene, including gene deletions and larger contiguous gene deletions. Some of the latter involve the neighboring gene BTK, resulting in agammaglobulinemia. By next-generation mate-pair sequencing we have mapped the chromosomal deletion breakpoints of one MTS case and three XLA-MTS cases and used breakpoint-spanning PCR to fine map the breakpoints by Sanger sequencing. Two of the XLA-MTS cases presented with large deletions (63.5 and 27.2 kb), and the junctional regions were characterized by long stretches of microhomology, indicating that the events have emerged through homologous recombination. Conversely, the MTS case exhibited a small 2 bp region of microhomology, and the regions were not characterized by extensive microhomology. The third XLA-MTS case had a more complex breakpoint, including a 59 bp inverted insertion, thus at least four breakpoints were involved in this event. In conclusion, mate-pair library generation combined with next-generation sequencing is an efficient method for breakpoint identification, also in regions characterized by repetitive elements.
Subject(s)
Deaf-Blind Disorders , Dystonia , Intellectual Disability , Optic Atrophy , Deaf-Blind Disorders/genetics , Dystonia/genetics , Humans , Intellectual Disability/genetics , Membrane Transport Proteins/genetics , Mitochondrial Precursor Protein Import Complex Proteins , Optic Atrophy/geneticsABSTRACT
Myotonic dystrophy type 1 (DM1) is a multisystem disorder, caused by expansion of a CTG trinucleotide repeat in the 3'-untranslated region of the DMPK gene. The repeat expansion is somatically unstable and tends to increase in length with time, contributing to disease progression. In some individuals, the repeat array is interrupted by variant repeats such as CCG and CGG, stabilising the expansion and often leading to milder symptoms. We have characterised three families, each including one person with variant repeats that had arisen de novo on paternal transmission of the repeat expansion. Two individuals were identified for screening due to an unusual result in the laboratory diagnostic test, and the third due to exceptionally mild symptoms. The presence of variant repeats in all three expanded alleles was confirmed by restriction digestion of small pool PCR products, and allele structures were determined by PacBio sequencing. Each was different, but all contained CCG repeats close to the 3'-end of the repeat expansion. All other family members had inherited pure CTG repeats. The variant repeat-containing alleles were more stable in the blood than pure alleles of similar length, which may in part account for the mild symptoms observed in all three individuals. This emphasises the importance of somatic instability as a disease mechanism in DM1. Further, since patients with variant repeats may have unusually mild symptoms, identification of these individuals has important implications for genetic counselling and for patient stratification in DM1 clinical trials.
Subject(s)
Myotonic Dystrophy/genetics , Phenotype , Trinucleotide Repeat Expansion , Adult , Aged , Alleles , Female , Humans , Male , Middle Aged , Myotonic Dystrophy/pathology , Myotonin-Protein Kinase/genetics , PedigreeABSTRACT
[This corrects the article DOI: 10.1371/journal.pone.0174166.].
ABSTRACT
OBJECTIVE: High sensitivity plasma cardiac troponin-I (cTnI) is emerging as a strong predictor of cardiac events in a variety of settings. We have explored its utility in patients with myotonic dystrophy type 1 (DM1). METHODS: 117 patients with DM1 were recruited from routine outpatient clinics across three health boards. A single measurement of cTnI was made using the ARCHITECT STAT Troponin I assay. Demographic, ECG, echocardiographic and other clinical data were obtained from electronic medical records. Follow up was for a mean of 23 months. RESULTS: Fifty five females and 62 males (mean age 47.7 years) were included. Complete data were available for ECG in 107, echocardiography in 53. Muscle Impairment Rating Scale score was recorded for all patients. A highly significant excess (p = 0.0007) of DM1 patients presented with cTnI levels greater than the 99th centile of the range usually observed in the general population (9 patients; 7.6%). Three patients with elevated troponin were found to have left ventricular systolic dysfunction (LVSD), compared with four of those with normal range cTnI (33.3% versus 3.7%; p = 0.001). Sixty two patients had a cTnI level < 5ng/L, of whom only one had documented evidence of LVSD. Elevated cTnI was not predictive of severe conduction abnormalities on ECG, or presence of a cardiac device, nor did cTnI level correlate with muscle strength expressed by Muscle Impairment Rating Scale score. CONCLUSIONS: Plasma cTnI is highly elevated in some ambulatory patients with DM1 and shows promise as a tool to aid cardiac risk stratification, possibly by detecting myocardial involvement. Further studies with larger patient numbers are warranted to assess its utility in this setting.
Subject(s)
Myocardium/pathology , Myotonic Dystrophy/pathology , Troponin I/blood , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/diagnosis , Adult , Aged , Biomarkers/blood , Echocardiography , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myotonin-Protein Kinase/genetics , Young AdultABSTRACT
We present a generic, multidisciplinary approach for improving our understanding of novel missense variants in recently discovered disease genes exhibiting genetic heterogeneity, by combining clinical and population genetics with protein structural analysis. Using six new de novo missense diagnoses in TBL1XR1 from the Deciphering Developmental Disorders study, together with population variation data, we show that the ß-propeller structure of the ubiquitous WD40 domain provides a convincing way to discriminate between pathogenic and benign variation. Children with likely pathogenic mutations in this gene have severely delayed language development, often accompanied by intellectual disability, autism, dysmorphology and gastrointestinal problems. Amino acids affected by likely pathogenic missense mutations are either crucial for the stability of the fold, forming part of a highly conserved symmetrically repeating hydrogen-bonded tetrad, or located at the top face of the ß-propeller, where 'hotspot' residues affect the binding of ß-catenin to the TBLR1 protein. In contrast, those altered by population variation are significantly less likely to be spatially clustered towards the top face or to be at buried or highly conserved residues. This result is useful not only for interpreting benign and pathogenic missense variants in this gene, but also in other WD40 domains, many of which are associated with disease.
Subject(s)
Developmental Disabilities/diagnosis , Developmental Disabilities/genetics , Genetic Heterogeneity , Mutation, Missense , Nuclear Proteins/chemistry , Receptors, Cytoplasmic and Nuclear/chemistry , Repressor Proteins/chemistry , beta Catenin/chemistry , Amino Acid Sequence , Child , Child, Preschool , Developmental Disabilities/metabolism , Developmental Disabilities/pathology , Female , Gene Expression , Genetics, Population , Humans , Hydrogen Bonding , Male , Models, Molecular , Molecular Sequence Data , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Prognosis , Protein Binding , Protein Domains , Protein Structure, Secondary , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism , Sequence Alignment , beta Catenin/genetics , beta Catenin/metabolismABSTRACT
OBJECTIVE: To expand the clinical phenotype of autosomal dominant congenital spinal muscular atrophy with lower extremity predominance (SMA-LED) due to mutations in the dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1) gene. METHODS: Patients with a phenotype suggestive of a motor, non-length-dependent neuronopathy predominantly affecting the lower limbs were identified at participating neuromuscular centers and referred for targeted sequencing of DYNC1H1. RESULTS: We report a cohort of 30 cases of SMA-LED from 16 families, carrying mutations in the tail and motor domains of DYNC1H1, including 10 novel mutations. These patients are characterized by congenital or childhood-onset lower limb wasting and weakness frequently associated with cognitive impairment. The clinical severity is variable, ranging from generalized arthrogryposis and inability to ambulate to exclusive and mild lower limb weakness. In many individuals with cognitive impairment (9/30 had cognitive impairment) who underwent brain MRI, there was an underlying structural malformation resulting in polymicrogyric appearance. The lower limb muscle MRI shows a distinctive pattern suggestive of denervation characterized by sparing and relative hypertrophy of the adductor longus and semitendinosus muscles at the thigh level, and diffuse involvement with relative sparing of the anterior-medial muscles at the calf level. Proximal muscle histopathology did not always show classic neurogenic features. CONCLUSION: Our report expands the clinical spectrum of DYNC1H1-related SMA-LED to include generalized arthrogryposis. In addition, we report that the neurogenic peripheral pathology and the CNS neuronal migration defects are often associated, reinforcing the importance of DYNC1H1 in both central and peripheral neuronal functions.
Subject(s)
Cytoplasmic Dyneins/genetics , Muscular Atrophy, Spinal/genetics , Mutation , Adolescent , Adult , Aged, 80 and over , Brain/pathology , Child , Child, Preschool , Cohort Studies , Family , Humans , Infant , Leg/pathology , Leg/physiopathology , Middle Aged , Muscular Atrophy, Spinal/pathology , Muscular Atrophy, Spinal/physiopathology , Phenotype , Young AdultSubject(s)
Aortic Aneurysm, Thoracic/genetics , Aortic Dissection/genetics , Heart Valve Diseases/genetics , Mitral Valve , Mutation/genetics , Transforming Growth Factor beta2/genetics , Adult , Aged , Aortic Dissection/physiopathology , Aortic Aneurysm, Thoracic/physiopathology , Female , Genetic Association Studies , Heart Valve Diseases/physiopathology , Humans , Male , Middle Aged , Mitral Valve/pathologySubject(s)
Abnormalities, Multiple/diagnosis , Cleft Lip/diagnosis , Cleft Palate/diagnosis , Heart Septal Defects, Atrial/diagnosis , Thumb/abnormalities , Adult , Child , Ear, External/abnormalities , Eye Abnormalities/diagnosis , Genetic Association Studies , Humans , Infant , Male , Maxilla/abnormalities , Micrognathism/diagnosis , Nose/abnormalities , SyndromeABSTRACT
The association of progressive episodic dystonia and learning disability with distinctive neuroimaging findings may lead to consideration of atypical Pantothenate Kinase Associated Neurodegeneration (PKAN) and investigations directed towards that diagnosis. Recent reports indicate that deficiency of dihydrolipoamide acetyltransferase, the E2 component of the pyruvate dehydrogenase complex, may present similarly, and that this disorder should also be considered in the differential diagnosis. We describe two sisters with early onset episodic dystonia and pyruvate dehydrogenase deficiency caused by defects in the E2 subunit. Both have neuroimaging features similar to previously described patients and have mutations in the DLAT gene. As this condition is potentially treatable with a ketogenic diet, the possibility of this diagnosis should be considered in similar cases.
Subject(s)
Dystonia/etiology , Pyruvate Dehydrogenase Complex Deficiency Disease/complications , Autoantigens/genetics , Cells, Cultured , Child , Diet, Ketogenic/methods , Dihydrolipoyllysine-Residue Acetyltransferase/genetics , Dystonia/diet therapy , Dystonia/genetics , Dystonia/pathology , Female , Fibroblasts/enzymology , Fibroblasts/pathology , Genetic Testing/methods , Humans , Magnetic Resonance Imaging/methods , Mitochondrial Proteins/genetics , Mutation/genetics , Pyruvate Dehydrogenase Complex Deficiency Disease/diet therapy , Pyruvate Dehydrogenase Complex Deficiency Disease/pathologyABSTRACT
A novel X-chromosome linked phenotype is reported. Three affected males had learning disability in early childhood and subsequently developed progressive ataxia, dystonia, and spasticity with death at ages 9, 14 and 19 years. Two female obligate carriers had learning difficulties with psychosis in one case. A third, possible carrier had learning difficulties and epilepsy. A family study indicates that this inherited syndrome is most likely due to an unreported MECP2 variant, p.V122A, located in the methyl binding domain of the MECP2 protein. The clinical features are similar to those present in the newly reported MECP2 duplication syndrome. Non-progressive neuropsychiatric symptoms in female relatives of a male child with learning disability, ataxia and progressive spasticity may constitute a clue to inherited, MECP2 pathogenesis.